Hossein Borghaei

30.2k total citations · 5 hit papers
258 papers, 9.0k citations indexed

About

Hossein Borghaei is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hossein Borghaei has authored 258 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 214 papers in Oncology, 167 papers in Pulmonary and Respiratory Medicine and 42 papers in Molecular Biology. Recurrent topics in Hossein Borghaei's work include Lung Cancer Treatments and Mutations (141 papers), Cancer Immunotherapy and Biomarkers (109 papers) and Lung Cancer Research Studies (67 papers). Hossein Borghaei is often cited by papers focused on Lung Cancer Treatments and Mutations (141 papers), Cancer Immunotherapy and Biomarkers (109 papers) and Lung Cancer Research Studies (67 papers). Hossein Borghaei collaborates with scholars based in United States, Spain and Germany. Hossein Borghaei's co-authors include Julie R. Brahmer, Laura Q.M. Chow, Scott Gettinger, Scott Antonia, Naiyer A. Rizvi, Rosalyn A. Juergens, Shirish M. Gadgeel, Frances A. Shepherd, Matthew D. Hellmann and David E. Gerber and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Hossein Borghaei

246 papers receiving 8.9k citations

Hit Papers

Carboplatin and pemetrexed with or without pembrolizumab ... 2015 2026 2018 2022 2016 2016 2015 2016 2016 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
    2016 1.1k citations Corey J. Langer, Hossein Borghaei et al. profile →
  2. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
    2016 700 citations Hossein Borghaei et al. profile →
  3. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
    2015 462 citations Hossein Borghaei et al. profile →
  4. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 394 citations Hossein Borghaei et al. Journal of Clinical Oncology profile →
  5. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 350 citations Hossein Borghaei et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hossein Borghaei United States 43 7.2k 4.6k 1.9k 1.4k 1.0k 258 9.0k
Todd M. Bauer United States 50 5.4k 0.8× 4.2k 0.9× 1.4k 0.7× 2.9k 2.2× 1.5k 1.5× 264 8.6k
Michael Smylie Canada 30 7.2k 1.0× 4.4k 1.0× 1.6k 0.9× 2.4k 1.8× 1.0k 1.0× 92 9.1k
Reshma Rangwala United States 18 7.0k 1.0× 4.4k 1.0× 1.8k 1.0× 1.4k 1.1× 1.2k 1.2× 41 9.2k
Craig Devoe United States 17 10.3k 1.4× 3.9k 0.9× 4.5k 2.4× 2.3k 1.7× 1.3k 1.3× 47 12.7k
Scott Gettinger United States 58 10.3k 1.4× 6.8k 1.5× 2.8k 1.5× 2.8k 2.1× 1.7k 1.7× 258 13.2k
Jean‐Pierre Delord France 43 5.5k 0.8× 2.0k 0.4× 1.7k 0.9× 2.2k 1.6× 1.1k 1.1× 260 8.4k
Mark M. Awad United States 48 7.8k 1.1× 5.8k 1.3× 1.3k 0.7× 2.4k 1.8× 1.7k 1.7× 275 10.9k
Patrick M. Forde United States 40 4.0k 0.6× 2.7k 0.6× 1.1k 0.6× 934 0.7× 645 0.6× 186 5.7k
Laura Q.M. Chow United States 44 9.1k 1.3× 4.6k 1.0× 3.0k 1.6× 2.9k 2.1× 1.6k 1.6× 159 12.4k
Emiliano Calvo Spain 45 6.0k 0.8× 2.7k 0.6× 1.7k 0.9× 3.1k 2.3× 1.1k 1.1× 340 9.3k

Countries citing papers authored by Hossein Borghaei

Since Specialization
Citations

This map shows the geographic impact of Hossein Borghaei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hossein Borghaei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hossein Borghaei more than expected).

Fields of papers citing papers by Hossein Borghaei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hossein Borghaei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hossein Borghaei. The network helps show where Hossein Borghaei may publish in the future.

Co-authorship network of co-authors of Hossein Borghaei

This figure shows the co-authorship network connecting the top 25 collaborators of Hossein Borghaei. A scholar is included among the top collaborators of Hossein Borghaei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hossein Borghaei. Hossein Borghaei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hirsch, Fred R., Paul A. Bunn, Peter Ujházy, et al.. (2024). Calls to action on lung cancer management and research. The Oncologist. 29(12). e1634–e1645. 1 indexed citations
2.
Italiano, Antoine, Hossein Borghaei, Sanjay Popat, et al.. (2024). 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study. Immuno-Oncology Technology. 24. 100747–100747. 3 indexed citations
3.
Rodríguez, Luis Paz-Ares, Enriqueta Felip, Myung‐Ju Ahn, et al.. (2024). PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304). Journal of Thoracic Oncology. 19(7). e34–e34. 1 indexed citations
4.
5.
6.
Elliott, Andrew, Wendy Cozen, Evanthia T. Roussos Torres, et al.. (2024). Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8526–8526. 1 indexed citations
7.
Espinoza, Magdalena, Andrew Elliott, Joanne Xiu, et al.. (2024). Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nature Cancer. 5(7). 1121–1129. 11 indexed citations
8.
Barlési, Fabrice, Enriqueta Felip, Sanjay Popat, et al.. (2024). Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).. Journal of Clinical Oncology. 42(16_suppl). TPS8653–TPS8653. 4 indexed citations
9.
Bagnyukova, Tetyana, et al.. (2024). Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers. Cancer Research Communications. 4(5). 1227–1239. 6 indexed citations
10.
Kozono, David, Xing Hua, Michael C. Wu, et al.. (2024). Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Journal of Thoracic Oncology. 19(12). 1618–1629. 3 indexed citations
11.
Borghaei, Hossein, Melissa L. Johnson, Edward B. Garon, et al.. (2023). LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S1308–S1308. 4 indexed citations
12.
Fernandez, Sandra V., Shilpa Rao, Fathima Sheriff, et al.. (2023). Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing. International Journal of Molecular Sciences. 24(21). 15779–15779. 2 indexed citations
13.
Skoulidis, Ferdinandos, Martin Schüler, Jennifer Moriatis Wolf, et al.. (2021). MA14.03 Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib. Journal of Thoracic Oncology. 16(10). S929–S930. 1 indexed citations
14.
Jabbour, Salma K., Baerin Houghton, Andrew Robinson, et al.. (2020). Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867. International Journal of Radiation Oncology*Biology*Physics. 108(3). e135–e136.
15.
Jonna, Sushma, Rebecca Feldman, Jeffrey Swensen, et al.. (2019). Detection of NRG1 Gene Fusions in Solid Tumors. Clinical Cancer Research. 25(16). 4966–4972. 155 indexed citations
16.
Goff, Laura W., Roger B. Cohen, Jordan Berlin, et al.. (2015). A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(9). 2146–2154. 26 indexed citations
17.
Kurzrock, Razelle, Peter M. Voorhees, Corey Casper, et al.. (2013). A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clinical Cancer Research. 19(13). 3659–3670. 166 indexed citations
18.
Cohen, R.J., Navesh Sharma, Jian Q. Yu, et al.. (2010). A phase I radiation dose escalation of stereotactic body radiotherapy for malignant lung tumors. Journal of Biomedical Science and Engineering. 3(4). 351–358. 2 indexed citations
19.
O’Brien, Susan, Ellin Berman, Hossein Borghaei, et al.. (2009). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 7(9). 984–1023. 175 indexed citations
20.
Borghaei, Hossein, Michael Millenson, Russell J. Schilder, et al.. (2004). Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non‐Hodgkin lymphoma. Cancer. 101(9). 2034–2041. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Todd M. Bauer Breakdown of academic impact, for papers by Michael Smylie Breakdown of academic impact, for papers by Reshma Rangwala Breakdown of academic impact, for papers by Craig Devoe Breakdown of academic impact, for papers by Scott Gettinger Breakdown of academic impact, for papers by Jean‐Pierre Delord Breakdown of academic impact, for papers by Mark M. Awad Breakdown of academic impact, for papers by Patrick M. Forde Breakdown of academic impact, for papers by Laura Q.M. Chow Breakdown of academic impact, for papers by Emiliano Calvo
Rankless by CCL
2026